734 related articles for article (PubMed ID: 25735223)
1. Monitoring therapeutic response of human ovarian cancer to trastuzumab by SPECT imaging with (99m)Tc-peptide-Z(HER2:342).
Zhang J; Zhao X; Wang S; Wang N; Han J; Jia L; Ren X
Nucl Med Biol; 2015 Jun; 42(6):541-6. PubMed ID: 25735223
[TBL] [Abstract][Full Text] [Related]
2. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
Ahlgren S; Wållberg H; Tran TA; Widström C; Hjertman M; Abrahmsén L; Berndorff D; Dinkelborg LM; Cyr JE; Feldwisch J; Orlova A; Tolmachev V
J Nucl Med; 2009 May; 50(5):781-9. PubMed ID: 19372467
[TBL] [Abstract][Full Text] [Related]
3. (99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors.
Tran T; Engfeldt T; Orlova A; Sandström M; Feldwisch J; Abrahmsén L; Wennborg A; Tolmachev V; Karlström AE
Bioconjug Chem; 2007; 18(6):1956-64. PubMed ID: 17944527
[TBL] [Abstract][Full Text] [Related]
4. SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe
Li L; Wu Y; Wang Z; Jia B; Hu Z; Dong C; Wang F
J Nucl Med; 2017 May; 58(5):821-826. PubMed ID: 28104744
[TBL] [Abstract][Full Text] [Related]
5. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments.
Tang Y; Scollard D; Chen P; Wang J; Holloway C; Reilly RM
Nucl Med Commun; 2005 May; 26(5):427-32. PubMed ID: 15838425
[TBL] [Abstract][Full Text] [Related]
6. Biodistribution characteristics and SPECT imaging of (99m)Tc-RET and (99m)Tc-REG in human lung cancer xenografts.
Xie WH; Zhang B; Wang LH; Liu CY; Chang C; Lei B; Wu YW
Cancer Biother Radiopharm; 2015 Apr; 30(3):117-24. PubMed ID: 25714734
[TBL] [Abstract][Full Text] [Related]
7. Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence.
Engfeldt T; Orlova A; Tran T; Bruskin A; Widström C; Karlström AE; Tolmachev V
Eur J Nucl Med Mol Imaging; 2007 May; 34(5):722-733. PubMed ID: 17146656
[TBL] [Abstract][Full Text] [Related]
8. Imaging of HER2-Positive Tumors in NOD/SCID Mice with Pertuzumab Fab-Hexahistidine Peptide Immunoconjugates Labeled with [
Facca VJ; Al-Saden N; Ku A; Reilly RM
Mol Imaging Biol; 2021 Aug; 23(4):495-504. PubMed ID: 33479914
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Evaluation of
Oroujeni M; Rinne SS; Vorobyeva A; Loftenius A; Feldwisch J; Jonasson P; Chernov V; Orlova A; Frejd FY; Tolmachev V
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803361
[TBL] [Abstract][Full Text] [Related]
10. 99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule.
Engfeldt T; Tran T; Orlova A; Widström C; Feldwisch J; Abrahmsen L; Wennborg A; Karlström AE; Tolmachev V
Eur J Nucl Med Mol Imaging; 2007 Nov; 34(11):1843-53. PubMed ID: 17565496
[TBL] [Abstract][Full Text] [Related]
11. A novel multivalent (99m)Tc-labeled EG2-C4bpα antibody for targeting the epidermal growth factor receptor in tumor xenografts.
Li C; Zhang Y; Wang L; Feng H; Xia X; Ma J; Yuan H; Gao B; Lan X
Nucl Med Biol; 2015 Jun; 42(6):547-54. PubMed ID: 25779037
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of 99mTc-peptide-ZHER2:342 Affibody® molecule for in vivo molecular imaging.
Zhang JM; Zhao XM; Wang SJ; Ren XC; Wang N; Han JY; Jia LZ
Br J Radiol; 2014 Jan; 87(1033):20130484. PubMed ID: 24273251
[TBL] [Abstract][Full Text] [Related]
13. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
McLarty K; Cornelissen B; Cai Z; Scollard DA; Costantini DL; Done SJ; Reilly RM
J Nucl Med; 2009 Aug; 50(8):1340-8. PubMed ID: 19617342
[TBL] [Abstract][Full Text] [Related]
14. (186)Re-maSGS-Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours.
Orlova A; Tran TA; Ekblad T; Karlström AE; Tolmachev V
Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):260-9. PubMed ID: 19771426
[TBL] [Abstract][Full Text] [Related]
15. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
Orlova A; Wållberg H; Stone-Elander S; Tolmachev V
J Nucl Med; 2009 Mar; 50(3):417-25. PubMed ID: 19223403
[TBL] [Abstract][Full Text] [Related]
16. Diversity of RGD radiotracers in monitoring antiangiogenesis of flavopiridol and paclitaxel in ovarian cancer xenograft-bearing mice.
Yang G; Sun H; Kong Y; Hou G; Han J
Nucl Med Biol; 2014; 41(10):856-62. PubMed ID: 25195014
[TBL] [Abstract][Full Text] [Related]
17. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.
Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM
J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729
[TBL] [Abstract][Full Text] [Related]
18. An improved
Khodadust F; Ahmadpour S; Aligholikhamseh N; Abedi SM; Hosseinimehr SJ
Eur J Med Chem; 2018 Jan; 144():767-773. PubMed ID: 29291444
[TBL] [Abstract][Full Text] [Related]
19. The Potential Usefulness of
Avan Z; Biabani Ardakani J; Talebpour Amiri F; Abedi SM; Hosseinimehr SJ
Cancer Biother Radiopharm; 2022 Nov; 37(9):862-869. PubMed ID: 32898439
[No Abstract] [Full Text] [Related]
20. Development of
Rainone P; Riva B; Belloli S; Sudati F; Ripamonti M; Verderio P; Colombo M; Colzani B; Gilardi MC; Moresco RM; Prosperi D
Int J Nanomedicine; 2017; 12():3447-3461. PubMed ID: 28496321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
